他泽司他(tazemetostat)2024年的价格是多少钱一盒?

The price of tazemetostat in 2024

The price of the Japanese version of tazemetostat is about $15,000 per box, and the specification is 200mg*56 tablets, but it is not fixed due to various factors.

Efficacy of tazemetostat

Tazemetostat, a first-in-class, oral, potent, EZH2 inhibitor, can exert anti-tumor effects by inhibiting EZH2 enzyme activity. As the world's first EZH2 inhibitor, tazemetostat can inhibit the proliferation of tumor cells by inhibiting overactive EZH2 function and regulating the transcription of genes involved in cell cycle regulation and terminal differentiation.

Effects of tazemetostat in the treatment of epithelioid sarcoma

In an open-label, phase 2 basket study, patients were enrolled in seven different cohorts of patients with INI1-negative solid tumors or synovial sarcoma. Patients with histologically confirmed locally advanced or metastatic epithelioid sarcoma were treated with tazemetostat 800 mg orally twice daily in consecutive 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent.

Trial Results

At the data cutoff date, 9 of 62 patients (15%) had experienced an objective response. With a median follow-up of 13-8 months, the median duration of response has not been reached. Disease control was achieved at 32 weeks in 16 patients (26%). Median time to response was 3-9 months. The median progression-free survival was 5-5 months and the median overall survival was 19-0 months.

Trial Conclusion

Tazemetostat works well and shows clinical activity in patients with advanced epithelioid sarcoma characterized by INI1/SMARCB1 loss. Tazemetostat has the potential to improve outcomes for patients with advanced epithelioid sarcoma.

Tazemetostat in follicular lymphoma

An open-label, single-arm, phase 2 trial in adults (≥18 years) with histologically confirmed follicular lymphoma (grade 1, 2, 3a, or 3b), relapsed or refractory to two or more systemic therapies, Eastern Cooperative Oncology Group performance status 0-2, and sufficient tumor tissue for Central detection of EZH2 mutational status. Patients received 800 mg orally twice daily for 28 days.

Trial results

The median follow-up time of the EZH2WT cohort was 35-9 months. The median duration of response was 10-9 months in the EZH2mut cohort and 13-0 months in the EZH2WT cohort; the median progression-free survival was 13-8 months and 11-1 months respectively. The objective response rate was 69% (31 of 45 patients) in the EZH2mut cohort and 35% (19 of 54 patients) in the EZH2WT cohort.

Trial Conclusion

For heavily pretreated patients with relapsed or refractory follicular lymphoma, tazemetostat monotherapy showed clinically meaningful and durable responses and was generally well tolerated. Tazemetostat is a novel treatment for patients with follicular lymphoma.

Recommended hot articles:

References

[1.] Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. doi: 10.1016/S1470-2045(20)30451-4. Epub 2020 Oct 6. PMID: 33035459.

[2.]Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj GL, Dickinson M, Jurczak W, Kazmierczak M, Opat S, Radford J, Schmitt A, Yang J, Whalen J, Agarwal S, Adib D, Salles G. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. Epub 2020 Oct 6. PMID: 33035457; PMCID: PMC8427481.